General Updates

iuv; Alpa Laboratories Ltd. 3312, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India Phone No. : +91 731-429 4567 Fax No. : +91 730-429 4444 Email : mktgdom@alpalabs.in CIN : L85195MP1988PLC004446 29'" July, 2026 To, To, Listing Department, Listing Department, BSE Limited. National Stock Exchange of India Limited. Rotunda Building, P J Towers ‘Exchange Plaza’, C-1, Block G, Dalal Street, Fort, Bandra - Kurla Complex, Mumbai — 400 001 : Bandra (E), Mumbai - 400 051 Scrip Code: 532878 Scrip Code: ALPA Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the Company has accorded approval in principle for exploring the proposed promotion and incorporation of an overseas company in the Federal Republic of Nigeria under the proposed name "Alpa Biopharm Limited" (or such other name as may be approved by the competent authority), in association with Blueseal Pharmaceuticals Limited, Nigeria, subject to applicable statutory, regulatory and other necessary approvals, wherever required. The proposed entity, if incorporated, is intended to undertake pharmaceutical and healthcare- related business activities. The proposed shareholding, capital contribution, investment, governance structure and other terms, if any, shall be considered separately in accordance with the applicable laws and necessary approvals. This disclosure is being made at the stage of approval in principle only. The proposed company has not been incorporated as on the date of this disclosure, and no investment has been made by the Company. Appropriate disclosures, if required, shall be made upon the occurrence of any material event. You are requested to take the same on records. For ALPA LABORATORIES LIMITED Malowctrrn MAHENDRA SINGH CHAWLA DIRECTOR DIN 00362058